Flexible Work
AARP Skills Builder
Flexible Work
ON-DEMAND WEBINARS
Drug Prices
Social Security
Medicare & Medicaid
Caregiving
LONG-TERM CARE
State Guides
Prepare to Care Guides
End of Life
Home Technology
Get Happier
POSSIBILITIES OF AI
Relationships
Home Health
Leaving AARP.org Website
You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.
BrandAmp by AARP provides the opportunity for our highly vetted marketing partners to share their expert knowledge, insights and storytelling with loyal and engaged readers like you. Each piece of paid content is created in collaboration with the disclosed advertiser and AARP Media Sales’ content development team.
BrandAmp by AARP content is designed to uphold AARP standards of excellence and inspire conversation. Only advertisers who have gone through the strictest reviews are cleared to bring their message directly to members using all of AARP media properties (AARP.org, social media, email newsletters and our print publications). Our pledge to members is work with brands whose products and services are of value to the 50+ audience; and are committed to the type of compelling, informative, entertaining and useful content members are accustomed to seeing within AARP media properties.
You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.
The U.S. Senate passed an AARP-supported bill Thursday that aims to speed access to lower-priced prescription drugs by making it harder for big drug companies to keep less expensive generic versions from coming to market.
The bipartisan Affordable Prescriptions for Patients Act of 2023, which now goes to the House for a vote, applies to companies making a class of drugs known as biologics, which are used to treat conditions that commonly affect older adults, such as cancer, multiple sclerosis and rheumatoid arthritis.
The bill would limit the number of patents a drug manufacturer can use in patent disputes with competitors hoping to develop generic versions of these drugs, known as biosimilars.
U.S. patent laws are set up to help drugmakers recoup their investment in developing innovative treatments by allowing them to sell their product exclusively for a number of years after bringing a new drug to market.
AARP is your fierce defender on the issues that matter to people 50-plus. Read more about how we’re fighting for you every day in Congress and across the country.
But some companies are “abusing the system,” said Sen. John Cornyn (R-Texas), who sponsored the bill with Sen. Richard Blumenthal (D-Conn.). “They’re taking extreme steps to maintain their exclusivity on the drug and keep the money rolling in.”
The bill passed unanimously in the Senate without a roll call vote. It addresses a tactic known as patent thicketing, where drug companies apply for multiple patents — sometimes hundreds — covering minor changes to the same drug, to protect it from competition.
AARP on Thursday applauded Senate lawmakers for passing the bill, which we endorsed last year along with other measures aimed at reining in high prescription drug costs.
Sign up to become an AARP activist on prescription drugs and other issues important to people 50 and older.
“Older Americans, who often rely on several prescription drugs to protect their health, deserve timely access to affordable medication,” said Nancy LeaMond, AARP’s chief advocacy and engagement officer. “For far too long, some drug companies have been able to use patent laws to stifle competition and keep lifesaving medications out of patients’ reach.”
Bringing down the cost of prescription drugs has long been a priority for AARP. In 2022, we were instrumental in helping to pass a historic prescription drug law that is lowering prices for millions of Medicare enrollees.
Read more about our efforts to lower prescription drug costs and keep up with AARP’s health coverage.
More From AARP
10 Prescription Drugs With Excessive Price Hikes
AARP report finds hundreds of common medications outpace inflation